Melanoma in patients with Li‑Fraumeni syndrome (Review)

Sandru,Florica; Dumitrascu,Mihai Cristian; Petca,Aida; Carsote,Mara; Petca,Razvan-Cosmin; Ghemigian,Adina

doi:10.3892/etm.2021.10998

Melanoma in patients with Li‑Fraumeni syndrome (Review)

Authors:
- Florica Sandru
- Mihai Cristian Dumitrascu
- Aida Petca
- Mara Carsote
- Razvan-Cosmin Petca
- Adina Ghemigian
View Affiliations

Affiliations: Department of Dermatology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Obstetrics and Gynecology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Endocrinology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Urology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania
Published online on: November 24, 2021 https://doi.org/10.3892/etm.2021.10998
Article Number: 75

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Li‑Fraumeni syndrome (LFS) is a cancer‑prone, autosomal dominant syndrome caused by underlying germline gene mutations of TP53, a tumor‑suppressor gene encoding the p53 protein with a major role in apoptosis, DNA repair and cell cycle regulation. Cumulative cancer incidence for LFS patients by the age of 70 years is 80‑100%, mostly involving adrenocortical carcinoma, brain tumors, bone and soft tissue sarcomas, leukemia and female breast cancer from the age of 20 years. Dominant negative TP53 variant is correlated with an increased tumorigenesis risk in LFS. Sporadic TP53 mutations are related to almost half of global cancers since p53 in addition to p73 protein represent essential players in anticancer cellular protection. Epidemiological aspects concerning skin cancers, especially malignant melanoma (MM), in LFS are less clear. A low level of statistical evidence demonstrates LFS cases with pediatric MM, multiple MM, spitzoid MM, atypical presentations, mucosal and uveal MM. Retrospective cohorts indicate a higher cumulative risk than the general population by the age of 70 years for MM and basal cell carcinoma. Non‑syndromic and syndromic TP53 mutations are a major pathway of metastasis, including MM. In LHS, an important level of awareness involves skin cancers despite not being a part of the typical malignancy‑containing picture. Additional data are crucially needed. However, at least one dermatologic control is a step in the multidisciplinary panel of surveillance of these patients; but in cases with benign and pre‑malign pigmentations, serial dermatoscopy and full body photography are recommended for early melanoma detection in order to improve the prognosis and to reduce the overall malignancy burden.

View Figures

View References

1	Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R and Evans DG: European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 28:1379–1386. 2020.PubMed/NCBI View Article : Google Scholar
2	Miranda Alcalde B, Villa Alcázar M, Martínez Romera I and López Ibor B: The importance of Li-Fraumeni syndrome, a hereditary cancer predisposition disorder. Arch Argent Pediatr. 119:e11–e17. 2021.PubMed/NCBI View Article : Google Scholar
3	Fortuno C, Lee K, Olivier M, Pesaran T, Mai PL, de Andrade KC, Attardi LD, Crowley S, Evans DG, Feng BJ, et al: Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat. 42:223–236. 2021.PubMed/NCBI View Article : Google Scholar
4	Wade KS, Estes JM and Kline RC: Genetics and the Gynecologic Patient. Ochsner J. 20:446–451. 2020.PubMed/NCBI View Article : Google Scholar
5	Ueki A and Hirasawa A: Molecular features and clinical management of hereditary gynecological cancers. Int J Mol Sci. 21(9504)2020.PubMed/NCBI View Article : Google Scholar
6	Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS and Savage SA: Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 122:3673–3681. 2016.PubMed/NCBI View Article : Google Scholar
7	Monti P, Menichini P, Speciale A, Cutrona G, Fais F, Taiana E, Neri A, Bomben R, Gentile M, Gattei V, et al: Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? Front Oncol. 10(593383)2020.PubMed/NCBI View Article : Google Scholar
8	Zawacka-Pankau JE: The undervalued avenue to reinstate tumor suppressor functionality of the p53 protein family for improved cancer therapy-drug repurposing. Cancers (Basel). 12(2717)2020.PubMed/NCBI View Article : Google Scholar
9	Levine AJ: p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 20:471–480. 2020.PubMed/NCBI View Article : Google Scholar
10	Fortuno C, Pesaran T, Mester J, Dolinsky J, Yussuf A, McGoldrick K, James PA and Spurdle AB: Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing. Cancer Genet. 248-249:11–17. 2020.PubMed/NCBI View Article : Google Scholar
11	Volc SM, Ramos CRN, Galvão HCR, Felicio PS, Coelho AS, Berardineli GN, Campacci N, Sabato CDS, Abrahao-Machado LF, Santana IVV, et al: The Brazilian TP53 mutation (R337H) and sarcomas. PLoS One. 15(e0227260)2020.PubMed/NCBI View Article : Google Scholar
12	Amadou A, Achatz MIW and Hainaut P: Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: Temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol. 30:23–29. 2018.PubMed/NCBI View Article : Google Scholar
13	Consul N, Amini B, Ibarra-Rovira JJ, Blair KJ, Moseley TW, Taher A, Shah KB and Elsayes KM: Li-Fraumeni syndrome and Whole-body MRI screening: Screening guidelines, imaging features, and impact on patient management. AJR Am J Roentgenol. 216:252–263. 2021.PubMed/NCBI View Article : Google Scholar
14	Grasparil AD II, Gottumukkala RV, Greer MC and Gee MS: Whole-body MRI surveillance of cancer predisposition syndromes: Current best practice guidelines for use, performance, and interpretation. AJR Am J Roentgenol. 215:1002–1011. 2020.PubMed/NCBI View Article : Google Scholar
15	Iwasaki T, Mizumoto M, Numajiri H, Oshiro Y, Suzuki R, Moritani K, Eguchi M, Ishii E and Sakurai H: Re-irradiation using proton therapy for radiation-induced secondary cancer with Li-Fraumeni syndrome: A case report and review of literature. J Cancer Res Ther. 16:1524–1527. 2020.PubMed/NCBI View Article : Google Scholar
16	Eulo V, Lesmana H, Doyle LA, Nichols KE and Hirbe AC: Secondary sarcomas: Biology, presentation, and clinical care. Am Soc Clin Oncol Educ Book. 40:1–12. 2020.PubMed/NCBI View Article : Google Scholar
17	Pang LK, Pena M, Zhao R and Lee DF: Modeling of osteosarcoma with induced pluripotent stem cells. Stem Cell Res. 49(102006)2020.PubMed/NCBI View Article : Google Scholar
18	Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P and Rutkowski P: Molecular biology of osteosarcoma. Cancers (Basel). 12(2130)2020.PubMed/NCBI View Article : Google Scholar
19	Schneider KW, Cost NG, Schultz KAP, Svihovec S and Suttman A: Germline predisposition to genitourinary rhabdomyosarcoma. Transl Androl Urol. 9:2430–2440. 2020.PubMed/NCBI View Article : Google Scholar
20	Sandru F, Carsote M, Valea A, Albu SE, Petca RC and Dumitrascu MC: Somatostatinoma: Beyond neurofibromatosis type 1 (Review). Exp Ther Med. 20:3383–3388. 2020.PubMed/NCBI View Article : Google Scholar
21	Evans DG, Woodward ER, Bajalica-Lagercrantz S, Oliveira C and Frebourg T: Germline TP53 testing in breast cancers: Why, when and how? Cancers (Basel). 12(3762)2020.PubMed/NCBI View Article : Google Scholar
22	Le AN, Harton J, Desai H, Powers J, Zelley K, Bradbury AR, Nathanson KL, Shah PD, Doucette A, Freedman GM, et al: Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Res Treat. 181:181–188. 2020.PubMed/NCBI View Article : Google Scholar
23	Piombino C, Cortesi L, Lambertini M, Punie K, Grandi G and Toss A: Secondary prevention in hereditary breast and/or ovarian cancer syndromes other than BRCA. J Oncol. 2020(6384190)2020.PubMed/NCBI View Article : Google Scholar
24	Fortuno C, James PA and Spurdle AB: Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat. 39:1764–1773. 2018.PubMed/NCBI View Article : Google Scholar
25	Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RDNG, Cotti GC, Hoff PM, Fragoso MCBV and Estevez-Diz MDP: Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 19:47–53. 2020.PubMed/NCBI View Article : Google Scholar
26	Orr BA, Clay MR, Pinto EM and Kesserwan C: An update on the central nervous system manifestations of Li-Fraumeni syndrome. Acta Neuropathol. 139:669–687. 2020.PubMed/NCBI View Article : Google Scholar
27	Xiong Y, Zhang Y, Xiong S and Williams-Villalobo AE: A Glance of p53 functions in brain development, neural stem cells, and brain cancer. Biology (Basel). 9(285)2020.PubMed/NCBI View Article : Google Scholar
28	Valdez JM, Nichols KE and Kesserwan C: Li-Fraumeni syndrome: A paradigm for the understanding of hereditary cancer predisposition. Br J Haematol. 176:539–552. 2017.PubMed/NCBI View Article : Google Scholar
29	Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, et al: Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 5(a003210)2019.PubMed/NCBI View Article : Google Scholar
30	Jouinot A and Bertherat J: Diseases predisposing to adrenocortical malignancy (Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and carney Complex). Exp Suppl. 111:149–169. 2019.PubMed/NCBI View Article : Google Scholar
31	Petr EJ and Else T: Adrenocortical carcinoma (ACC): When and why should we consider germline testing? Presse Med. 47:e119–e125. 2018.PubMed/NCBI View Article : Google Scholar
32	Carsote M, Ghemigian A, Terzea D, Gheorghisan-Galateanu AA and Valea A: Cystic adrenal lesions: Focus on pediatric population (a review). Clujul Med. 90:5–12. 2017.PubMed/NCBI View Article : Google Scholar
33	Kamihara J, Rana HQ and Garber JE: Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat. 35:654–662. 2014.PubMed/NCBI View Article : Google Scholar
34	Baek YS, Seo JY, Song JY, Lee SY, Kim A and Jeon J: Li-Fraumeni syndrome presenting as cutaneous melanoma in a child: Case report and review of literature. J Eur Acad Dermatol Venereol. 33:e174–e175. 2019.PubMed/NCBI View Article : Google Scholar
35	Akay BN, Okcu Heper A, Topcu V and Farabi B: A rare case of multiple cutaneous melanomas in Li-Fraumeni syndrome: A coincidental association or a component of the syndrome? Australas J Dermatol. 60:e214–e216. 2019.PubMed/NCBI View Article : Google Scholar
36	Curiel-Lewandrowski C, Speetzen LS, Cranmer L, Warneke JA and Loescher LJ: Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. Arch Dermatol. 147:248–250. 2011.PubMed/NCBI View Article : Google Scholar
37	Kollipara R, Cooley LD, Horii KA, Hetherington ML, Leboit PE, Singh V and Zwick DL: Spitzoid melanoma in a child with Li-Fraumeni syndrome. Pediatr Dev Pathol. 17:64–69. 2014.PubMed/NCBI View Article : Google Scholar
38	Jacquemus J, Perron E, Pissaloux D, Alberti L and de la Fouchardière A: Atypical cutaneous melanocytic tumours arising in two patients with Li-Fraumeni syndrome. Pathology. 49:801–805. 2017.PubMed/NCBI View Article : Google Scholar
39	Klein JD and Kupferman ME: Li-Fraumeni syndrome presenting as mucosal melanoma: Case report and treatment considerations. Head Neck. 39:E20–E22. 2017.PubMed/NCBI View Article : Google Scholar
40	Hajkova N, Hojny J, Nemejcova K, Dundr P, Ulrych J, Jirsova K, Glezgova J and Ticha I: Germline mutation in the TP53 gene in uveal melanoma. Sci Rep. 8(7618)2018.PubMed/NCBI View Article : Google Scholar
41	Calvete O, Garcia-Pavia P, Domínguez F, Bougeard G, Kunze K, Braeuninger A, Teule A, Lasa A, Ramón Y, Cajal T, et al: The wide spectrum of POT1 gene variants correlates with multiple cancer types. Eur J Hum Genet. 25:1278–1281. 2017.PubMed/NCBI View Article : Google Scholar
42	Giavedoni P, Ririe M, Carrera C, Puig S and Malvehy J: Familial melanoma associated with Li-Fraumeni syndrome and atypical mole syndrome: Total-body digital photography, dermoscopy and confocal microscopy. Acta Derm Venereol. 97:720–723. 2017.PubMed/NCBI View Article : Google Scholar
43	Sabater-Marco V, Ferrando-Roca F, Morera-Faet A, García-García JA, Bosch SB and López-Guerrero JA: Primary cutaneous leiomyosarcoma arising in a patient With Li-Fraumeni Syndrome: A neoplasm with unusual histopathologic features and loss of heterozygosity at TP53 Gene. Am J Dermatopathol. 40:225–227. 2018.PubMed/NCBI View Article : Google Scholar
44	Nieuwenburg SA, Adan F, Ruijs MWG, Sonke GS, van Leerdam ME and Crijns MB: Cumulative risk of skin cancer in patients with Li-Fraumeni syndrome. Fam Cancer. 19:347–351. 2020.PubMed/NCBI View Article : Google Scholar
45	Park KJ, Choi HJ, Suh SP, Ki CS and Kim JW: Germline TP53 mutation and clinical characteristics of Korean patients with Li-Fraumeni syndrome. Ann Lab Med. 36:463–468. 2016.PubMed/NCBI View Article : Google Scholar
46	Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, et al: Familial melanoma-astrocytoma syndrome: Synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol. 36:213–221. 2017.PubMed/NCBI View Article : Google Scholar
47	Hsieh CC and Shen CH: The potential of targeting P53 and HSP90 overcoming acquired MAPKi-resistant melanoma. Curr Treat Options Oncol. 20(22)2019.PubMed/NCBI View Article : Google Scholar
48	Pandey R, Johnson N, Cooke L, Johnson B, Chen Y, Pandey M, Chandler J and Mahadevan D: TP53 Mutations as a driver of metastasis signaling in advanced cancer patients. Cancers (Basel). 13(597)2021.PubMed/NCBI View Article : Google Scholar
49	Alos L, Fuster C, Castillo P, Jares P, Garcia-Herrera A, Marginet M, Agreda F, Arance A, Gonzalvo E, Garcia M, et al: TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas. Ann Transl Med. 8(1218)2020.PubMed/NCBI View Article : Google Scholar
50	Loureiro JB, Abrantes M, Oliveira PA and Saraiva L: P53 in skin cancer: From a master player to a privileged target for prevention and therapy. Biochim Biophys Acta Rev Cancer. 1874(188438)2020.PubMed/NCBI View Article : Google Scholar
51	Guo L, Kang JS, Kang NJ and Choi YW: S-petasin induces apoptosis and inhibits cell migration through activation of p53 pathway signaling in melanoma B16F10 cells and A375 cells. Arch Biochem Biophys. 692(108519)2020.PubMed/NCBI View Article : Google Scholar
52	Carsote M, Valea A, Dumitru N, Terzea D, Petrova E, Albu S, Buruiana A and Ghemigian A: Metastases in daily endocrine practice. Arch Balkan Med Union. 51:478–482. 2016.
53	Baloescu R, Carsote M, Albu SE and Valea A: Multiple surgeries and long-term endocrine follow-up in a MEN2A syndrome. J Surgical Sciences. 4:1–4. 2015.
54	Paduraru DN, Nica A, Carsote M and Valea A: Adrenalectomy for Cushing's syndrome: Do's and don'ts. J Med Life. 9:334–341. 2016.PubMed/NCBI
55	Poiana C, Carsote M, Chirita C, Terzea D, Paun S and Beuran M: Giant adrenal cyst: Case study. J Med Life. 3:308–313. 2010.PubMed/NCBI
56	Caruntu C, Boda D, Constantin C, Caruntu A and Neagu M: Catecholamines increase in vitro proliferation of murine B16F10 melanoma cells. Acta Endocrinol. 10:545–558. 2014.
57	Lupu M, Caruntu A, Caruntu C, Papagheorghe LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki M, et al: Neuroendocrine factors: The missing link in non melanoma skin cancer. Oncol Rep. 38:1327–1340. 2017.PubMed/NCBI View Article : Google Scholar
58	Grange JD, Duquesne N, Roubeyrol F, Branisteanu D, Sandon K, Fleury J, Gerard JP, Chauvel P, Pinzaru G, Jean-Louis B and Bievelez B: Double irradiation for macroscopic radioresistance or recurrence of melanomas of the posterior uvea: Clinical, ballistic, thera-peutic and prognostic aspects. Series of 19 cases among 462 patients. J Fr Ophtalmol. 22:1054–1063. 1999.PubMed/NCBI(In French).
59	Ancuceanu R, Dinu M, Neaga I, Laszlo FG and Boda D: Development of QSAR machine learning-based models to forecast the effect of substances on malignant melanoma cells. Oncol Lett. 17:4188–4196. 2019.PubMed/NCBI View Article : Google Scholar
60	Stefan O, Tudor G, Constantinescu C, Luca C, Boda D, Caruntu C, Cioplea M, Nichita L and Zurac SA: E-cadherin and N-cadherin expression pattern in common melanocytic nevi. Virchows Archiv. 475 (Suppl):S28. 2019.
61	Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett. 11:3354–3360. 2016.PubMed/NCBI View Article : Google Scholar